New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 2, 2014
08:51 EDTIMUCImmunoCellular upgraded at Roth Capital
As previously reported, Roth Capital upgraded ImmunoCellular to Buy from Neutral. The firm upgraded shares following the update to the the Phase II ICT-107 study in front-line glioblastoma. The analyst believes a true addressable patient population has been identified and is optimistic on the next regulatory steps. Price target raised to $3 from $2.
News For IMUC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 27, 2016
06:04 EDTIMUCImmunoCellular enters into sponsored research agreement with Eduardo Davila, PhD
ImmunoCellular announced it has entered into a sponsored research agreement with Eduardo Davila, PhD, Associate Professor of Microbiology and Immunology at the University of Maryland School of Medicine, and the University of Maryland, Baltimore. The agreement includes three projects, which together have the potential to improve the efficacy of dendritic cell, T-cell, and combination immunotherapies for cancer and lead to enhancements to both of ImmunoCellular's dendritic cell and Stem-to-T-cell platforms.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use